Skip to main content
. 2003 Jun;162(6):1913–1926. doi: 10.1016/S0002-9440(10)64325-8

Figure 2.

Figure 2.

In vitro and in vivo growth properties of Tet-FGF-2 and AS-VEGF/Tet-FGF-2 transfectants. A: AS-VEGF/Tet-FGF-2 A5 and C1 clones (▵, ▴) and mock Tet-FGF-2 C7 and A4 clones (○, •) were seeded at 25,000 cells/well in 24-well plates in complete cell culture medium. At the indicated time points, cells were trypsinized and counted. B: Cells were transplanted subcutaneously in nude mice (1 × 106 cells/animal) and tumor growth was reported. Each point is the mean ± SE of five tumors. Statistical analysis of tumor volume by orthogonal comparison analysis of variance at day 45 showed a significant difference (P < 0.001) between Tet-FGF-2 and AS-VEGF/Tet-FGF-2 clones (**). At sacrifice, three Tet-FGF-2 A4 tumors and three AS-VEGF/Tet-FGF-2 C1 tumors were analyzed for AS-VEGF mRNA expression (arrow) by Northern blotting (inset). Uniform loading of the gel was assessed by methylene blue staining of the filter.